Clinical OMICs - Issue 4 - (Page 5)
Here Comes Everybody
I
f there's anything more boring than social networking technology, it's social
networking pundits. That said, one such pundit, Clay Shirky, the author of Here
Comes Everybody: The Power of Organizing without Organizations, makes a good
point: Change doesn't happen when society adopts new technology, it happens when
society adopts new behaviors.
"Communications tools
don't get socially
interesting until they get
technologically boring."
-Clay Shirky
Here at Clinical OMICS, we appreciate the observation all the more as we intensify our
Twitter efforts. Twitter is boring. And we expect that it will become even more boring-
at least until it finally becomes subordinate to user behaviors, which are interesting.
ISSUE No. 3
MAY 15, 2014
Innovative Practices, Actionable Results
At present, according to educators at Michigan State University (MSU), just 15% of
researchers use Twitter, mostly to find collaborators and disseminate their work
and the work of others. The MSU educators, disappointed that Twitter's potential
for teaching remains dormant, actually called for universities to include social networking habits when meting out promotions and tenured positions. Mistake! If
you want more social networking, just wait. It is becoming part of the background.
Future Cancer Care
Anticipating "Panomics"
with Bioinformatics
Bringing Informed
Interpretation
to Vexing Variants
Best Clinical Apps
Innovator: Leroy Hood
New Products & More
What could be more boring to researchers than self-promotion? Yet that is a key driver
of the growth of Twitter among scientists. According to a study from the University of
Miami, scientists are tweeting published findings to "communicate research to a broad
audience of other researchers, decision makers, journalists, and the general public."
A digital publication of GEN, a Mary Ann Liebert, Inc. company
This result was accompanied by other revelations: "Twitter provides a large
virtual department of colleagues that can help to rapidly generate, share,
and refine new ideas. As ideas become manuscripts, Twitter can be used
as an informal arena for the pre-review of works in progress." So, it appears
that unabashed careerism may be accompanied by less selfish behaviors.
"Although some scientists have mixed feelings about using Twitter for
scholarly purposes, it's only a matter of time before the scientific community embraces social media," concluded one of the study's authors.
Here at Clinical OMICS, we agree. We also make this promise: As we use Twitter to
build a clinical omics community, we will remember our social networking forum is
nothing special. What's special is the content. What's important is the growth of this
emerging discipline. What's necessary is the emergence of new diagnostic and treatment options informed by clinical omics.
www.clinicalomics.com
Clinical OMICs on Twitter-as
inevitable as it is indispensable.
May 29, 2014 Clinical OMICs
5
https://twitter.com/ClinicalOMICs
http://www.clinicalomics.com
Table of Contents for the Digital Edition of Clinical OMICs - Issue 4
Contents
Clinical OMICs - Issue 4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss1
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss12
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss11
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss10
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss1
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue15
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue14
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue13
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue12
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue11
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue10
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue1
https://www.nxtbookmedia.com